- Home
- AAON vs EXEL Comparison
AAON vs EXEL Comparison
Compare AAON & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAON
- EXEL
- Stock Information
- Founded
- AAON 1988
- EXEL 1994
- Country
- AAON United States
- EXEL United States
- Employees
- AAON N/A
- EXEL N/A
- Industry
- AAON Industrial Machinery/Components
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AAON Industrials
- EXEL Health Care
- Exchange
- AAON Nasdaq
- EXEL Nasdaq
- Market Cap
- AAON 10.7B
- EXEL 10.0B
- IPO Year
- AAON N/A
- EXEL 2000
- Fundamental
- Price
- AAON $130.43
- EXEL $34.37
- Analyst Decision
- AAON Buy
- EXEL Buy
- Analyst Count
- AAON 4
- EXEL 17
- Target Price
- AAON $133.00
- EXEL $32.18
- AVG Volume (30 Days)
- AAON 410.9K
- EXEL 1.7M
- Earning Date
- AAON 11-07-2024
- EXEL 02-04-2025
- Dividend Yield
- AAON 0.25%
- EXEL N/A
- EPS Growth
- AAON 11.31
- EXEL 441.02
- EPS
- AAON 2.28
- EXEL 1.55
- Revenue
- AAON $1,209,555,000.00
- EXEL $2,081,598,000.00
- Revenue This Year
- AAON $6.80
- EXEL $20.59
- Revenue Next Year
- AAON $24.92
- EXEL $1.50
- P/E Ratio
- AAON $56.27
- EXEL $22.41
- Revenue Growth
- AAON 8.34
- EXEL 17.31
- 52 Week Low
- AAON $68.38
- EXEL $19.20
- 52 Week High
- AAON $144.07
- EXEL $36.97
- Technical
- Relative Strength Index (RSI)
- AAON 51.14
- EXEL 51.61
- Support Level
- AAON $127.57
- EXEL $34.30
- Resistance Level
- AAON $135.38
- EXEL $36.22
- Average True Range (ATR)
- AAON 3.98
- EXEL 0.75
- MACD
- AAON -1.20
- EXEL -0.29
- Stochastic Oscillator
- AAON 35.54
- EXEL 25.09
About AAON AAON Inc.
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. AAON's products serve the commercial and industrial new construction and replacement markets, primarily in North America.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.